ChromaDex (NASDAQ:CDXC - Get Free Report) was downgraded by investment analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a research note issued on Wednesday.
Several other equities research analysts have also weighed in on the stock. HC Wainwright increased their target price on shares of ChromaDex from $6.00 to $8.00 and gave the stock a "buy" rating in a report on Monday, November 4th. Roth Mkm raised their price objective on ChromaDex from $6.00 to $8.00 and gave the stock a "buy" rating in a research note on Wednesday, November 6th.
Check Out Our Latest Report on CDXC
ChromaDex Trading Up 6.3 %
Shares of NASDAQ:CDXC traded up $0.34 during midday trading on Wednesday, hitting $5.77. The company had a trading volume of 460,742 shares, compared to its average volume of 388,759. The firm has a fifty day simple moving average of $6.40 and a 200 day simple moving average of $4.40. The stock has a market cap of $440.73 million, a price-to-earnings ratio of 577.58 and a beta of 2.21. ChromaDex has a 12 month low of $1.36 and a 12 month high of $7.97.
ChromaDex (NASDAQ:CDXC - Get Free Report) last issued its earnings results on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter. The firm had revenue of $25.58 million for the quarter, compared to analysts' expectations of $23.70 million. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. During the same quarter last year, the business earned ($0.01) earnings per share. Equities analysts forecast that ChromaDex will post 0.04 EPS for the current fiscal year.
Insider Buying and Selling
In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the company's stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $6.19, for a total value of $230,026.59. Following the completion of the transaction, the director now owns 244,179 shares in the company, valued at $1,511,468.01. This represents a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 9.64% of the stock is owned by company insiders.
Hedge Funds Weigh In On ChromaDex
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CDXC. OneDigital Investment Advisors LLC lifted its holdings in shares of ChromaDex by 5.5% in the third quarter. OneDigital Investment Advisors LLC now owns 59,414 shares of the company's stock valued at $217,000 after purchasing an additional 3,097 shares in the last quarter. USA Financial Formulas acquired a new stake in ChromaDex in the 4th quarter valued at approximately $25,000. MetLife Investment Management LLC boosted its position in ChromaDex by 39.3% during the 3rd quarter. MetLife Investment Management LLC now owns 18,114 shares of the company's stock worth $66,000 after acquiring an additional 5,115 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of ChromaDex by 75.4% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,732 shares of the company's stock worth $72,000 after acquiring an additional 8,485 shares in the last quarter. Finally, Merriman Wealth Management LLC acquired a new stake in shares of ChromaDex in the second quarter valued at approximately $32,000. 15.41% of the stock is owned by institutional investors and hedge funds.
ChromaDex Company Profile
(
Get Free Report)
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Featured Stories
Before you consider ChromaDex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ChromaDex wasn't on the list.
While ChromaDex currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
